RTx-015 not checked

Ray Therapeutics, Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2/3 trial completes
Trials
1 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Retinitis Pigmentosa (RP), Inherited Retinal Diseases
Main trialPhase 2/3
“The purpose of this clinical trial is to evaluate the effectiveness and safety of a single injection into the eye of an investigational gene therapy in participants with retinitis pigmentosa (RP).”In the company’s words, NCT07901751 on ClinicalTrials.gov

Other drugs for Retinitis Pigmentosa (RP)

All 4 drugs for Retinitis Pigmentosa (RP)

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 2/3Recruiting Oct 2028 Study to Evaluate the Efficacy of a Single Intravitreal Injection of RTx-015 in Participants With Retinitis Pigmentosa (PERCEPT)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow RTx-015

Following is part of Solo: you see every change to RTx-015 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in